TY - JOUR T1 - Optimal use of COVID19 Ag-RDT screening at border crossings to prevent community transmission: a modeling analysis JF - medRxiv DO - 10.1101/2021.04.26.21256154 SP - 2021.04.26.21256154 AU - Joshua M Chevalier AU - Karla Therese L Sy AU - Sarah J Girdwood AU - Shaukat Khan AU - Heidi Albert AU - Amy Toporowski AU - Emma Hannay AU - Sergio Carmona AU - Brooke E Nichols Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/28/2021.04.26.21256154.abstract N2 - Background Countries around the world have implemented restrictions on mobility, especially cross-border travel to reduce or prevent SARS-CoV-2 community transmission. Rapid antigen testing (Ag-RDT), with on-site administration and rapid turnaround time may provide a valuable screening measure to ease cross-border travel while minimizing risk of local transmission. To maximize impact, we developed an optimal Ag-RDT screening algorithm for cross-border entry.Methods Using a previously developed mathematical model, we determined the daily number of imported COVID-19 cases that would generate no more than a relative 1% increase in cases over one month for different effective reproductive numbers (Rt) of the recipient country. We then developed an algorithm- for differing levels of Rt, arrivals per day, mode of travel, and SARS-CoV-2 prevalence amongst travelers-to determine the minimum proportion of people that would need Ag-RDT testing at border crossings to ensure no greater than the relative 1% community spread increase.Findings When daily international arrivals and/or COVID-19 prevalence amongst arrivals increases, the proportion of arrivals required to test using Ag-RDT increases. At very high numbers of international arrivals/COVID-19 prevalence, Ag-RDT testing is not sufficient to prevent increased community spread, especially for lower levels of Rt. In these cases, Ag-RDT screening would need to be supplemented with other measures to prevent an increase in community transmission.Interpretation An efficient Ag-RDT algorithm for SARS-CoV-2 testing depends strongly on Rt, volume of travel, proportion of land and air arrivals, test sensitivity, and COVID-19 prevalence among travelers.Funding USAID, Government of the NetherlandsCompeting Interest StatementThe authors have declared no competing interest.Funding StatementJMC, KTLS, SJG, and BEN were funded for this work by the Government of the Netherlands. BEN was funded for this work by United States Agency for International Development (USAID) through the following cooperative agreement: AID‐OAA‐A‐15‐00070.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data utilized in this manuscript has been referenced and is publicly available. ER -